GlassScriptPhysician profile
Akhil Raghuram
NPI 1851462725
$7,307.82
in general payments reported to CMS, 2019-2025
10 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 83% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $132 · 2021: $180 · 2022: $437 · 2023: $4,079 · 2024: $583 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,362 · Food and Beverage: $2,141 · Travel and Lodging: $690 · Education: $84.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,362.00 |
| Food and Beverage | $2,141.13 |
| Travel and Lodging | $689.91 |
| Education | $84.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $5,031.00 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $946.54 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $362.37 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $301.60 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $285.30 | 2022-2025 | Sunosi |
| Zoll Respicardia, INC. | $177.99 | 2024 | Remede System |
| Idorsia Pharmaceuticals US INC | $111.71 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $38.56 | 2019-2021 | |
| Lilly USA, LLC | $29.94 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $22.81 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akhil Raghuram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.